# EDGAR Filing Document

**Accession Number:** 0000811641
**File Stem:** 0001213900-25-057768
**Filing Date:** 2025-6
**Character Count:** 8914
**Document Hash:** c8b2079c6b8fbbfe46768ed7603907c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-057768.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001213900-25-057768

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250625

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMMUCELL CORP /DE/
- **CENTRAL INDEX KEY:** 0000811641
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 010382980
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12934
- **FILM NUMBER:** 251073486

**BUSINESS ADDRESS:**
- **STREET 1:** 56 EVERGREEN DR
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103
- **BUSINESS PHONE:** 2078782770

**MAIL ADDRESS:**
- **STREET 1:** 56 EVERGREEN DRIVE
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) <u>June 25, 2025</u>

---

| |
|:---|
| **ImmuCell Corporation** |
| (Exact name of registrant as specified in its charter) |

---

<u>DE</u> <u>001-12934</u> <u>01-0382980</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<u>56 Evergreen Drive Portland, Maine</u> <u>04103</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code <u>207-878-2770</u>

  <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) <br>

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) <br>

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) <br>

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $0.10 par value per share ICCC | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events**

On June 25, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its CEO Succession Planning Process.

The information in Item 8.01 and Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:

99.1 [Press Release of ImmuCell Corporation dated June 25, 2025.](ea024700601ex99-1_immucell.htm)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 25, 2025 | **IMMUCELL CORPORATION** | **IMMUCELL CORPORATION** |
|  | By: | /s/ Michael F. Brigham |
|  |  | President and Chief Executive Officer |
|  | By: | /s/ Timothy C. Fiori |
|  |  | Chief Financial Officer |

---

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of ImmuCell Corporation dated June 25, 2025](ea024700601ex99-1_immucell.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

**ImmuCell**

**ImmuCell Embarks on CEO Succession Planning Process**

 ****

***<u>For Immediate Release</u>***

**PORTLAND, Maine – June 25, 2025 – ImmuCell Corporation (Nasdaq: ICCC)** ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO.

"I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by early 2026," said Michael F. Brigham, President and CEO. "I originally joined ImmuCell in 1989 and am very grateful to have had the opportunity to serve as the President and CEO of this growing Company since 2000."

Mr. Brigham's prior additional responsibilities as principal financial officer have been transferred to the Company's recently hired Chief Financial Officer, Timothy C. Fiori. The Board of Directors' search process for a new CEO is already underway with the expectation that Mr. Brigham would be available to help transition his CEO responsibilities as well.

"While there is no set deadline, our goal is to identify and select a top-notch candidate by around year-end, and I am fully committed to the search for a new leader," continued Mr. Brigham. "I plan to remain until we find the optimal candidate, and I look forward to serving on our Board of Directors through my just elected term ending in June of 2026 and to continued Board service after that, subject to the vote of stockholders."

**<u>About ImmuCell:</u>**

ImmuCell Corporation (**Nasdaq: ICCC**) creates scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets **First Defense**<sup>®</sup>, which provides **Immediate Immunity**™ to newborn dairy and beef calves, and is developing **Re-Tain**<sup>®</sup>, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that hamper traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

---

| | |
|:---|:---|
| **Contacts:** | Michael F. Brigham, President and CEO<br> Timothy C. Fiori, CFO<br> ImmuCell Corporation<br> (207) 878-2770 |

---

Joe Diaz, Robert Blum and Joe Dorame

Lytham Partners, LLC

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(602) 889-9700

**<u>Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):</u>**

This Press Release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future operational performance; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.